Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) Equity Average (2016 - 2025)

Traws Pharma (TRAW) has disclosed Equity Average for 14 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • For Q4 2025, Equity Average rose 111.63% year-over-year to $2.0 million; the TTM value through Dec 2025 reached $2.0 million, up 111.63%, while the annual FY2025 figure was -$16.1 million, 53.92% down from the prior year.
  • Equity Average hit $2.0 million in Q4 2025 for Traws Pharma, down from $6.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $47.9 million in Q4 2021 and bottomed at -$53.8 million in Q3 2024.
  • Average Equity Average over 5 years is $13.2 million, with a median of $18.8 million recorded in 2023.
  • Year-over-year, Equity Average soared 420.86% in 2021 and then plummeted 421.87% in 2024.
  • Traws Pharma's Equity Average stood at $47.9 million in 2021, then crashed by 35.61% to $30.8 million in 2022, then plummeted by 59.16% to $12.6 million in 2023, then plummeted by 233.64% to -$16.8 million in 2024, then skyrocketed by 111.63% to $2.0 million in 2025.
  • According to Business Quant data, Equity Average over the past three periods came in at $2.0 million, $6.4 million, and $7.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.